CVS Health Corporation

As of June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh carries a market capitalization of 187.42B, placing it among publicly traded companies globally. Its enterprise value stands at 276.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh has 7.52B shares outstanding.

As of June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh trades at a trailing price-to-earnings ratio of 26.89. The price-to-sales ratio is 0.32, and the price-to-book ratio stands at 1.66.

As of June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh trades at an EV/EBITDA multiple of 15.19 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.48 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh trades at an EV/FCF ratio of 13.54, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 276.18B versus a market cap of 187.42B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 95.50, indicating elevated leverage, while an interest coverage ratio of 4.13 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh posted a return on equity (ROE) of 6.23, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.42 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.91, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.75, useful for judging operating efficiency across full business cycles. The company generates approximately 1.96M in revenue per employee across its workforce of 300,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 20.32 indicates how many times CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh recorded 1.28B in income tax expense. That works out to an effective tax rate of 15.59, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 8.21B, leaving 6.94B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 21.93, while the 200-day moving average is 21.23.

Over the twelve months ended June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh generated 589.09B in revenue and converted that into 6.94B in net income, yielding earnings per share of 0.92. EBITDA reached 18.18B, while operating income came in at 19.89B.

As of June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh holds 19.81B in cash and equivalents against 108.29B in total debt, resulting in a net debt position of 71.08B. Total book value stands at 113.11B, with working capital of -16.60B providing operational flexibility.

CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh produced 20.98B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.29B in capital expenditures, free cash flow totaled 16.69B - equivalent to 2.23 per share.

Over the twelve months ended June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh posted a gross margin of 14.15, reflecting its pricing power and cost economics. The operating margin of 3.38 and net profit margin of 1.18 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh paid dividends of 0.65 per share. The dividend payout ratio of 70.00 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.90, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.38, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh shareholders.

As of June 30, 2026, CVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh has an Altman Z-Score of 4.21, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.